G Iacoboni1, E Zucca1, M Ghielmini1, A Stathis2. 1. Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 2. Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. Electronic address: anastasios.stathis@eoc.ch.
Abstract
Background: The first-line treatment of diffuse large B-cell lymphoma (DLBCL) is the combination of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, curing approximately 60% of patients. Many clinical trials have been carried out over the last 10 years trying to improve the results of this treatment, but the appropriateness of their planning strategies could be rediscussed. Patients and methods: Reports of phase III trials evaluating the addition of molecularly targeted agents or new monoclonal antibodies to the classic R-CHOP backbone in first-line induction or maintenance treatment were reviewed. The trial design, primary end point, number of patients enrolled, patient selection criteria, treatment schedule and results were registered for each one. In addition, the phases I and II trials which preceded these phase III trials were also reviewed. Results: Among six phase III trials with results, only one trial evaluating lenalidomide maintenance after response to R-CHOP induction was positive and reached its primary end point. The other five trials did not show an improved outcome with the addition of the new agent. The preceding phases I and II trials were very heterogeneous in their end points and design. Even though most of these trials were considered positive, thus encouraging further investigation, so far they failed to predict the results of the subsequent phase III trials. Conclusion: The standard of care for DLBCL is still R-CHOP. Phase I/II trials failed to predict the results of subsequent phase III trials evaluating non-chemotherapeutic agents added to R-CHOP. The methodology of phase II trials evaluating new agents in DLBCL needs to be better defined in the future.
Background: The first-line treatment of diffuse large B-cell lymphoma (DLBCL) is the combination of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, curing approximately 60% of patients. Many clinical trials have been carried out over the last 10 years trying to improve the results of this treatment, but the appropriateness of their planning strategies could be rediscussed. Patients and methods: Reports of phase III trials evaluating the addition of molecularly targeted agents or new monoclonal antibodies to the classic R-CHOP backbone in first-line induction or maintenance treatment were reviewed. The trial design, primary end point, number of patients enrolled, patient selection criteria, treatment schedule and results were registered for each one. In addition, the phases I and II trials which preceded these phase III trials were also reviewed. Results: Among six phase III trials with results, only one trial evaluating lenalidomide maintenance after response to R-CHOP induction was positive and reached its primary end point. The other five trials did not show an improved outcome with the addition of the new agent. The preceding phases I and II trials were very heterogeneous in their end points and design. Even though most of these trials were considered positive, thus encouraging further investigation, so far they failed to predict the results of the subsequent phase III trials. Conclusion: The standard of care for DLBCL is still R-CHOP. Phase I/II trials failed to predict the results of subsequent phase III trials evaluating non-chemotherapeutic agents added to R-CHOP. The methodology of phase II trials evaluating new agents in DLBCL needs to be better defined in the future.
Authors: Martin D Berger; Sven Trelle; Annina E Büchi; Sabrina Jegerlehner; Codruta Ionescu; Thierry Lamy de la Chapelle; Urban Novak Journal: Haematologica Date: 2021-07-01 Impact factor: 9.941
Authors: Stefan Alig; Charles W Macaulay; David M Kurtz; Ulrich Dührsen; Andreas Hüttmann; Christine Schmitz; Michael C Jin; Brian J Sworder; Andrea Garofalo; Mohammad Shahrokh Esfahani; Barzin Y Nabet; Joanne Soo; Florian Scherer; Alexander F M Craig; Olivier Casasnovas; Jason R Westin; Gianluca Gaidano; Davide Rossi; Mark Roschewski; Wyndham H Wilson; Michel Meignan; Maximilian Diehn; Ash A Alizadeh Journal: J Clin Oncol Date: 2021-04-28 Impact factor: 50.717
Authors: Stuart W Hicks; Chiara Tarantelli; Alan Wilhem; Eugenio Gaudio; Min Li; Alberto J Arribas; Filippo Spriano; Roberta Bordone; Luciano Cascione; Katharine C Lai; Qifeng Qiu; Monica Taborelli; Davide Rossi; Georg Stussi; Emanuele Zucca; Anastasios Stathis; Callum M Sloss; Francesco Bertoni Journal: Haematologica Date: 2019-02-07 Impact factor: 9.941
Authors: Lennart Raman; Malaïka Van der Linden; Ciel De Vriendt; Bliede Van den Broeck; Kristoff Muylle; Dries Deeren; Franceska Dedeurwaerdere; Sofie Verbeke; Amélie Dendooven; Katrien De Grove; Saskia Baert; Kathleen Claes; Björn Menten; Fritz Offner; Jo Van Dorpe Journal: Haematologica Date: 2022-01-01 Impact factor: 9.941